Chemotherapy plus PD-1 immunotherapy before surgery for locally advanced rectal cancer (CONTROL-01)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants receive three cycles (9 weeks) of CAPOX (oxaliplatin + capecitabine) combined with the PD-1 inhibitor tislelizumab as preoperative treatment, followed by a two-week rest and surgical resection with adjuvant therapy decided by postoperative pathology. Treatment may be modified or continued for patients who develop toxicity but still derive benefit, at the investigator's discretion. After stopping study treatment, safety follow-up occurs at about 30 and 90 days, then survival follow-up visits occur approximately every three months for a total follow-up of 36 months. Eligibility is confirmed by pathology, contrast-enhanced imaging, performance status, and routine laboratory tests.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be willing and able to provide written informed consent for the trial
* Age 18 years or greater
* Pathologically proven diagnosis of adenocarcinoma of the rectum
* Clinically determined to be stage T3 or T4, N0-N2, and M0
* Be fully active, able to carry on all pre-disease performance without restriction or Restricted in physically strenuous activity.
* Contrast-enhanced imaging of the abdomen and chest by CT to exclude distant metastases and provide local tumor stage
* Preoperative ECOG status score 0-1
* Preoperative ASA grade I-III
* Adequate bone marrow function
* Adequate renal and liver function
* No active second cancers
* Be willing and able to comply with all aspects of the protocol
* Women of childbearing potential must have used reliable contraception or have had a pregnancy test result within 7 days prior to enrollment. Be negative and willing to use an adequate method of contraception for the duration of the trial and for 8 weeks after the last administration of the trial drug.
* Adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,200 cells/mm3 Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 8.0 g/dl.
* Adequate hepatic function within within 28 days before registration on this study:total bilirubin must be ≤ ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation \> ULN to 1.5 x ULN due to Gilbert\'s disease or similar syndrome involving slow conjugation of bilirubin; and AST and ALT must be ≤3 x ULN for the lab If AST and/or ALT is ≥ ULN but ≤ 3 x ULN, serologic testing for Hepatitis B and C must be performed and results for viral infection must be negative.
* Adequate renal function within 28 days before randomization defined as serum creatinine ≤ 1.5 x ULN for the lab or calculated creatinine clearance \> 30 mL/min

Exclusion Criteria:

* Age less than 18 years
* Pregnant or breastfeeding women
* Prior invasive malignancy unless disease free for a minimum of three years
* Preoperative body temperature ≥ 38°C or concurrent infectious diseases requiring systemic therapy;
* Severe mental illness;
* Severe abnormal heart, lung and kidney function
* History of unstable angina pectoris or myocardial infarction within 6 months;
* History of cerebral infarction or cerebral hemorrhage within 6 months;
* Patients with abnormal coagulation function;
* Have a history of psychotropic drug abuse or have a mental disorder;
* Continuous use of glucocorticoids within 1 month (except topical application);
* Patient has participated in or is participating in other clinical studies (within 6 months);
* According to the judgment of the investigator, it endangers the patient\'s health or affects the experimental results.

Where it's running

• The affiliated hospital of Qingdao university
  Qingdao, Shandong, China Recruiting

Study contacts

• Study coordinator: Yun Lu
• Email: luyun@qdyy.cn
• Phone: 18661802231

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• PPISR for low- to mid-rectal cancer with anus-sparing aim

  This study tests whether Precision Partial Intersphincteric Resection can be safely used to remove certain rectal cancers while preserving the anus.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07849023

• Tislelizumab plus Anlotinib after chemoradiotherapy in limited-stage SCLC

  This phase II trial tests whether adding tislelizumab and anlotinib after chemoradiotherapy helps people with limited-stage small cell lung cancer stay cancer-free.

  Recruiting Phase 2 Yantai Yuhuangding Hospital · Yantai, Shandong · NCT07815223

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.